In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Somatix Therapy

Executive Summary

Company's Phase I GVAX gene therapy protocol for prostate cancer is the first approved by NIH's Recombinant DNA Advisory Committee under the new accelerated review procedures. GVAX is designed to produce an immune response that "seeks out and destroys remaining or metastatic tumors" by genetically modifying the patient's own cells to produced the immunostimulant GM-CSF, Somatix says. Trials of GVAX for renal cell carcinoma and advanced melanoma are already under way



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts